Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
about
Rivastigmine for Alzheimer's diseaseThe Yamaguchi fox/pigeon-imitation test, a brief cognitive performance rating tool, in a community-dwelling population: normative data for Japanese subjects - a preliminary study.Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based studyCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trialsCognitive function as an emerging treatment target for marijuana addictionCurrent and emerging drug treatment options for Alzheimer's disease: a systematic review.Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohortTreatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsEfficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.Differential diagnosis of depression and Alzheimer's disease with the Addenbrooke's Cognitive Examination-Revised (ACE-R)Predictors of long-term cognitive outcome in Alzheimer's diseaseCholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deteriorationNeuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study.A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.Management of patients with Alzheimer's disease: pharmacological treatment and quality of lifeDose and plasma concentration of galantamine in Alzheimer's disease - clinical application.100 years and counting: prospects for defeating Alzheimer's diseasePresent and prospective clinical therapeutic regimens for Alzheimer's disease.Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil.Treatment of Alzheimer's disease across the spectrum of severity.Progress update: Pharmacological treatment of Alzheimer's disease.Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore.Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment StrategyIn silico QSAR analysis of quercetin reveals its potential as therapeutic drug for Alzheimer's disease.Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Aspects of beta-amyloid as a biomarker for Alzheimer's disease.Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
P2860
Q24241686-09862079-4AC7-4D10-A5C8-6437A4CD477DQ30854550-6993F4CD-7E4C-4D82-A1DC-27DAA46D09D3Q33586027-8E7295C7-BFB2-4A94-BEB8-C923F69CF25BQ33694502-72779205-3610-4299-ADEC-9AC3A202BCD0Q33718205-A6319CA6-93F4-4AF0-9307-910B2EF751B2Q33912750-0A3CAA99-610E-4B0F-892F-D9F441A102C0Q34014237-D496EDB3-230A-4F2D-8B5C-93020F5B4D23Q34018386-97534EF1-3821-4B34-951C-BE799D186547Q34222721-03099086-D293-4D24-8D53-37B12CAD7FBFQ34402925-8D32E3F2-F848-4D20-B4EB-6CC17AB54072Q34409349-02D45192-073D-47C8-BC4E-D9672A008B51Q34466802-2FA30E1D-55A8-4F1D-BE7B-89126D45B43BQ34629649-7EEF045C-3E43-4FE2-B3B4-7AB3DEB38A6BQ34965949-16BBC608-5697-459A-9FDB-AB8F4A5DB53CQ35539649-C8B9E6CF-0AF4-43D2-9380-FD75CC27AB12Q35555782-BC15FCFA-92D1-4C73-B459-19230192612CQ35579243-D31C2903-B3AF-4FCC-83FE-3F67B4EB01C5Q36118948-F4463B16-0461-4A1B-86A9-8C6E37C8AA3EQ36226873-6A3DBA3B-F770-4038-9F14-11505561D034Q36325773-FD8D3B69-F1B0-4C41-BF1A-77E85E045056Q36482937-7A34AA14-639A-465D-848D-00CA8FE3AAEBQ36515587-FE5A22CF-334C-4477-984B-4A43546F9E13Q36632702-F2BF0FAC-BDC0-4433-8F99-140676BA95C2Q36643419-91769E30-5CCA-4C19-AEC5-4D634CE8327EQ36876447-42F03832-011E-4495-8434-B88E80EF47D8Q36897422-B26F02D4-8B7A-41EC-A71D-56471BD53A59Q36932284-250F2C9B-DC57-4E9F-ABDC-2574FF0037D8Q37017375-A268F733-FAE6-4109-B510-77B4AC76610DQ37129735-FB279819-8E1F-47E7-AD6D-B6E48CAB81DEQ37198579-E015E732-7BEF-4D68-B3DE-468385D64F0DQ37316293-DF0FEA46-D77A-4931-80CF-3DD094D5C653Q37396299-21DC9436-B146-41E0-8819-9BAE6734013EQ37503295-77F005C1-E31A-4EA7-83BB-F9163CF7DEC3Q37553489-68555529-CB87-467F-BB06-7F6A04148F2DQ37594804-4D7127D4-D532-4DC9-BE8D-19AC99163636Q37690649-23949AB5-3249-4CC0-828D-A69FD2AB0C6AQ37718557-8F416A45-63A8-4FB1-ADEF-CA241071B5E6Q37755129-49BF850E-74F9-4780-9BE9-61ADE36C2352Q40793617-4442F428-A09F-404D-A169-436C9396A848Q41588156-FB7F1B84-F3D0-46DC-8C62-C5F0415520A2
P2860
Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Metaanalysis of randomized tri ...... reatment of Alzheimer disease.
@en
Metaanalysis of randomized tri ...... reatment of Alzheimer disease.
@nl
type
label
Metaanalysis of randomized tri ...... reatment of Alzheimer disease.
@en
Metaanalysis of randomized tri ...... reatment of Alzheimer disease.
@nl
prefLabel
Metaanalysis of randomized tri ...... reatment of Alzheimer disease.
@en
Metaanalysis of randomized tri ...... reatment of Alzheimer disease.
@nl
P2093
P1476
Metaanalysis of randomized tri ...... reatment of Alzheimer disease.
@en
P2093
David Ames
Rosalind Lai
Tim Clayton
P304
P356
10.1176/APPI.AJGP.12.4.358
P577
2004-07-01T00:00:00Z